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Development of semi-automated devices that can reduce the hands-on time and
standardize the production of clinical-grade CAR T-cells, such as CliniMACS Prodigy
from Miltenyi, is key to facilitate the development of CAR T-cell therapies, especially
in academic institutions. However, the feasibility of manufacturing CAR T-cell products
from heavily pre-treated patients with this system has not been demonstrated yet.
Here we report and characterize the production of 28 CAR T-cell products in the
context of a phase I clinical trial for CD19+ B-cell malignancies (NCT03144583). The
system includes CD4-CD8 cell selection, lentiviral transduction and T-cell expansion
using IL-7/IL-15. Twenty-seven out of 28 CAR T-cell products manufactured met the full
list of specifications and were considered valid products. Ex vivo cell expansion lasted an
average of 8.5 days and had a mean transduction rate of 30.6 ± 13.44%. All products
obtained presented cytotoxic activity against CD19+ cells and were proficient in the
secretion of pro-inflammatory cytokines. Expansion kinetics was slower in patient’s cells
compared to healthy donor’s cells. However, product potency was comparable. CAR
T-cell subset phenotype was highly variable among patients and largely determined by
the initial product. TCM and TEM were the predominant T-cell phenotypes obtained. 38.7%
of CAR T-cells obtained presented a TN or TCM phenotype, in average, which are the
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subsets capable of establishing a long-lasting T-cell memory in patients. An in-depth
analysis to identify individual factors contributing to the optimal T-cell phenotype revealed
that ex vivo cell expansion leads to reduced numbers of TN, TSCM, and TEFF cells, while
TCM cells increase, both due to cell expansion and CAR-expression. Overall, our results
show for the first time that clinical-grade production of CAR T-cells for heavily pre-treated
patients using CliniMACS Prodigy system is feasible, and that the obtained products
meet the current quality standards of the field. Reduced ex vivo expansion may yield
CAR T-cell products with increased persistence in vivo.
Keywords: chimeric antigen receptor, CD19, leukemia, lymphoma, immunotherapy, CAR T-cell production,
CliniMACS Prodigy
INTRODUCTION
Adoptive T-cell transfer (ACT) immunotherapy is a field in
continuous expansion especially during the last three decades.
ACT involves ex vivo expansion of tumor-specific cells and
reinfusion into the patient. Among these therapies, the use of
Chimeric Antigen Receptor (CAR) T-cells for the treatment
of several hematologic malignancies has shown unprecedented
efficacy rates. Consequently, the development of these therapies
from bench to bedside has been done in an impressively short
amount of time (1–3).
CAR T-cells are genetically modified cells whose cytotoxic
activity has been redirected toward cancer cells with the aim of
eliminating the tumor. CARs are chimeric proteins composed
of an extracellular region responsible for binding to a particular
antigen and an intracellular region that promotes T-cell cytotoxic
activity and proliferation. CAR binding to the selected antigen is
usually mediated by a single chain variable fragment (scFv) of a
monoclonal antibody. The scFv-derived region results in aMHC-
independent interaction of the CAR with its ligand. This scFv is
combined with one or more intracellular co-stimulatory domains
(usually CD28 or 4-1BB) and a pro-activator cytotoxic domain
(CD3ζ) (4–6).
First great successes in the CAR T-cell field came from
studies using a 2nd generation CAR (including a co-stimulatory
domain) targeting the pan-B-cell lineage marker CD19. In
this studies by National Cancer Institute and University of
Pennsylvania, one patient with follicular lymphoma experienced
partial remission (7) and two out of three patients with
advanced refractory chronic lymphocytic leukemia (CLL)
obtained complete responses (8). Afterwards, these and several
other institutions including Memorial Sloan Kettering Cancer
Center and the Fred Hutchinson Cancer Research Center
pioneered several studies using slightly different CAR19
constructs, and confirmed response rates between 50 and 80% in
CLL, non-Hodgkin’s lymphoma (NHL) and acute lymphoblastic
leukemia (ALL) (9–14).
Currently, a lot of effort is being put in developing new CARs
to target other types of tumors. Anti-BCMA CAR has also shown
impressive response rates (around 90%) for multiple myeloma
(MM) (15–17). Also, other antigens such as CD30 and CD22
are currently being explored for the treatment of hematologic
malignancies (18–20). In the field of solid tumors, CAR T-cell
therapies have proven to be more challenging, so far. Initial
clinical trials in solid tumors have shown limited efficacy and high
toxicity (21–30). This fact can be attributed to several factors:
difficulty in finding tumor-specific antigens to target, poor T
cell infiltration in the tumor and immunosuppressive tumor
microenvironment, among others. The scientific community is
currently working in finding ways to overcome these challenges
(31, 32). As a result, dozens of clinical trials using 4th
generation CARs (Armored CARs, CAR T-cells containing
suicide genes and antibody-producing CARTs) for solid tumors
are ongoing (33–36).
The different clinical applications and the number of patients
waiting to receive a treatment are exponentially growing.
Accordingly, the number of institutions and centers that are
in need of being capable of performing CAR T-cell therapies
is also growing. In this context, developing systems that can
facilitate CART-cell production is crucial to help CART-cell field
move faster, thereby finding effective therapies for all kinds of
malignances and other diseases.
To this end, we have previously reported the development
and pre-clinical evaluation of a new anti-CD19 CAR, based on
the A3B1 antibody (37). Concomitantly, we have also established
a CAR T-cell (ARI-0001) production system at our institution
(Hospital Clinic de Barcelona). Our system is based on the use
of a closed semi-automatic bioreactor (CliniMACS Prodigy R©)
for ex vivo selection, transduction and expansion of CAR T-
cells. We are currently conducting a phase I clinical trial using
our novel anti-CD19 CAR for CD19+ B-cell malignancies
(NCT03144583). We have successfully prepared 28 ARI-0001 cell
products in the context of this clinical trial. Here, we present
the results and characteristics of the products obtained, thereby
demonstrating, for the first time, the feasibility of CAR T-cell
production in a relatively wide series of heavily pre-treated
patients using CliniMACS Prodigy system.
MATERIALS AND METHODS
Patients and Samples
At the time of submitting this manuscript, 28 products from
27 patients enrolled in phase I clinical trial for CD19+ B-cell
malignancies (NCT03144583) have been produced. Among the
27 patients, 22 had ALL (14 adult and eight pediatric patients),
four hadNHL and 1 CLL. All patients included in the clinical trial
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had relapsed of their disease. Patients’ pretreatment regimens are
summarized in Table 1.
Adult patients were subjected to leukocytapheresis at the
Apheresis Unit, Hospital Clínic, and pediatric patients at the
Apheresis Unit of Hospital Sant Joan deDéu/BST, after signing an
informed consent. Apheresis procedures were performed using
Amicus device (Fresenius Kabi, Lake Zurich, IL). A minimum
of 1 × 108 total T-cells diluted in 50ml of plasma were
required. This study has been approved by the Research Ethics
Comitee (CeIm) of Hospital Clinic. HCB/2017/0001. Clinical
trial: CART19-BE-01. Eudra: 2016-002972-29.
ARI-0001 Cell Production
Apheresis products were connected to CliniMACS Prodigy R©
system (Miltenyi Biotec) tubing set. Erythrocytes and platelets
were removed by density gradient centrifugation in the
Centricult unit. The remaining cells were selected using CD4
and CD8 coated magnetic beads. Selected cells were eluted
in the “Reapplication Bag.” After selection, 1 × 108 T-cells
(from reapplication bag) were used to initiate cell culture.
The remaining cells were cryopreserved in bags and vials to
be used as control cells for product quality assays and as a
backup in case of production failure. Cells were cultured using
TexMACS R© media supplemented with 3% human AB serum
(obtained from the blood bank. BST) and with 155 IU/mL
IL-7 and 290 IU/mL IL-15 (Miltenyi Biotec #170-076-111 and
#170-076-114, respectively). Cells were immediately activated
using TransACT GMP Grade (Miltenyi Biotec, Cat. N. 170-
076-156) and transduced 24h later using CAR19-containing
lentivirus at MOI = 10. A cell culture wash was programmed
48 h after transduction. The cells were then maintained in
culture with increasing shaking until the desired cell number was
reached (typically 7–10 days after cell culture initiation). Cells
were finally eluted in 100ml 0.9% NaCl + 1%HSA, aliquoted
according to the desired ARI-0001 cell dose and cryopreserved
until infusion.
The aim was to achieve two doses of ARI-0001 cells/patient.
The planned target cell dose varied depending on the patient’s
disease. Typically, 1 × 106 ARI-0001 cells/kg for patients with
ALL and CLL, and 5× 106 ARI-0001 cells/kg for NHL patients.
TABLE 1 | Patients’ pretreatment regimens.
Pat ID Age Sex Disease Lines of treatment prior to leukoapheresis Allogeneic HCT
T01 27 M ALL PETHEMA 2011, blinatumomab, radiotherapy Yes (+ DLI)
T02 25 M PMLBCL R-CHOP, R-ESHAP, autologous HCT, radiotherapy, brentuximab, GSK525762, nivolumab No
T03 7 F ALL SEHOP 2013, SEHOP 2016, inotuzumab, methotrexate + cyclophosphamide + anthracyclins + prednisone Yes (+ DLI)
T04 19 F PMLBCL R-CHOP, R-ESHAP, autologous HCT, radiotherapy, BURKIMAB, Gemcitabine + vinorelbine + procarbacine No
T05 51 M DLBCL BURKIMAB, autologous HCT, cyclophosphamide + prednisone, GSK525762, methotrexate, cyclophosphamide No
T06 20 F ALL PETHEMA 2011, PETHEMA 2008 Yes
T07 19 M ALL PETHEMA 2011, FLAG-Ida Yes
T08 53 F CLL FCR, BR, ibrutinib, venetoclax, obinutuzumab, idelalisib No
T09 8 M ALL SEHOP 2008, SEHOP 2013 No
T13 20 M ALL GRAAL 2003, FLAG-Ida, blinatumomab Yes (x2)
T11 34 F ALL PETHEMA 2011, Hyper-CVAD, inotuzumab Yes
T12 3 F ALL SEHOP 2013, SEHOP 2016, vincristine + prednisone Yes
T14 27 M ALL PETHEMA 2008, FLAG-Ida, PETHEMA 2011 Yes
T15 30 M ALL PETHEMA 2011, FLAG-Ida, FLAG-Ida + blinatumomab, FLAG-Ida, inotuzumab Yes (x2 + DLI)
T16 10 M ALL SEHOP 2013 Yes
T17 23 M ALL PETHEMA 2011, FLAG-Ida, PETHEMA 2008, BFM-90, inotuzumab Yes
T19 9 F ALL PETHEMA, SEHOP 2015, radiotherapy No
T20 35 M ALL PETHEMA 2011, FLAG-Ida, PETHEMA 2011, methotrexate + vincristine + dexamethasone Yes
T21 13 F ALL SEHOP 2013, SEHOP 2016, prednisone Yes
T22 29 M ALL PETHEMA 2008, dasatinib, FLAG-Ida + ponatinib, FCR Yes
T24 19 M ALL PETHEMA 2011, FLAG-Ida No
T25 47 F ALL PETHEMA 2011, FLAG-Ida, PETHEMA 2011 Yes
T26 8 F ALL SEHOP Yes
T27 22 M ALL PETHEMA 2008, FLAG-Ida, PETHEMA 2011 No
T30 31 M ALL PETHEMA 2008, blinatumomab Yes (+DLI)
T32 23 M ALL PETHEMA 2008, PETHEMA 2011, vindesine + prednisone, inotuzumab Yes (x2)
T34 45 F DLBCL R-CHOP, R-ESHAP, BURKIMAB, radiotherapy No
ALL, acute lymphoblastic leukemia; DLBCL, diffuse large B-cell lymphoma; PMLBCL, primary mediastinal large B-cell lymphoma; CLL, chronic lymphocytic leukemia; DLI, donor
lymphocyte infusion; HCT, hematopoietic cell transplantation; FCR, fludarabina + cyclophosphamide + rituximab; BR, bendamustina + rituximab; FLAG-Ida, fludarabina + cytarabine
+ idarubicin + G-CSF; PETHEMA, Spanish Program of Treatments in Hematology; SEHOP, Spanish Society of Pediatric Hematology & Oncology; GRAAL, Group for Research on Adult
Acute Lymphoblastic Leukemia.
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Monoclonal Antibodies
CAR19 expression was detected with an APC-conjugated
AffiniPureF(ab’)2-fragment goat-anti-mouse IgG (Jackson
ImmunoResearch Laboratories, 115-136-072). ARI-0001 cell
product composition was determined by flow cytometry using
staining with the following antibodies (all from BD): CD45-APC,
CD3-BV421, CD4-FITC, CD8-PerCPCy5.5, CD19-PECy7,
CD16-PE, CD56-PE.
For the T cell subset characterization experiments, CAR+
cells were detected using a CD19-Fc recombinant protein
chimera (R&D, Cat. N. 9269-CD-050) and a secondary
antibody FITC-Goat F(ab)2 anti-human IgG (Life Technologies,
Cat. N. H10101C). This staining was combined with the
following monoclonal antibodies (all from BD): CD3-BV421,
CD8-APC.Cy7, CD45RA-PECy7, CD45RO-APC, CCR7-
PerCPCy5.5, CD28-BV510, and CD95-PE (or CD27-PE). T
cell subpopulations were defined as follows: TN: CD45RA+,
CCR7+; TSCM: CD45RA+, CCR7+,CD95+; TCM: CD45RA–,
CCR7+; TEM: CD45RA-, CCR7- and TEFF: CD45RA+, CCR7−.
For intracellular cytokine measurement, the following
antibodies were used, all from BD: CD3-BV450, CD8-APC.H7,
CD4-BV500, IFNγ-PerCP.Cy5.5, TNFα-PE.
For repeated challenges experiment, the antibodies used
were the following, all from BD: CD3-APC, CD4-BV510, CD8-
APC.Cy7, CD19-PE.
For flow cytometry analyses, cells were acquired using a FACS
Canto II, BD and subsequently analyzed using FlowJo Software.
Product Quality Controls
Product potency assay was performed by flow cytometry as
described in Castella et al. (37). Real-time PCR was used to
measure number of copies/cell and to assess the presence of
replication-competent lentivirus (RCL) in the final product.
Primer sequences and PCR protocol has been described
previously (37). Product sterility, absence of mycoplasma,
endotoxin and adventitious virus was determined by a
certified laboratory using the technique specified in Table S1.
Adventitious virus included the determination of HIV virus
presence among others. Since conventional HIV detection
methods detect also the presence of the lentiviral transgene
used to transduce the cells, an alternative PCR assay based on
the detection of Env gene was used to discriminate between
HIV infection and lentiviral transduction. The primers used
to amplify Env gene are: Env_F: 5′CAATGTACACATGGA
ATTAGGCCA 3′ and Env_R: 5′ TTCTGGGTCCCCTCCTGA
GGA 3′.
Cytokine Measurement
Cytokine level was measured using Milliplex MAP Human
Cytokine/Chemokine Magnetic Bead panels (Millipore). A 10-
plex kit for IFNγ, IL-10, IL-1β, IL-6, TNFα, IL-12(P40), IL-17,
IL-2, IL-4, and IP-10, a 3-plex kit for IL-8, IL-15 and MIP1A (Cat
N. HCYTOMAG-60K) and a 1-plex kit for GranzymeB (Cat. N.
HCD8MAG-15K) were used. The assay was performed following
manufacturer’s instructions. Samples were run in a Luminex
200 system.
Alternatively, intracellular cytokine production (IFNγ and
TNFα) was measured by flow cytometry. Briefly, cells were
first labeled for extracellular markers CD4, CD8, and CD3 and
incubated 15min. Cells were then fixed using 1X BD lysing
solution (Cat. N. 349202) and incubated for an additional 15min.
After 2 washes, cells were permeabilized using FACS buffer
+ 0.1% saponin, and incubated for 15min. Cells were then
incubated with anti-IFNγ and anti-TNFα, for 30min at 4◦C.
After that, cells were washed in PBS and analyzed.
Small-Scale T Cell Expansions
0.5 × 106 T-cells were cultured with X-Vivo 15 Cell Medium
(Cultek, Cat. N. BE02-060Q), 5% AB human serum (Sigma,
Cat. N. H4522), penicillin-streptomycin (100µg/ml) and the
indicated cytokine: 50 IU/ml IL-2 (Miltenyi Biotec) or 155
IU/mL IL-7 and 290 IU/mL IL-15 (Miltenyi Biotec). Cytokines
were added to the media every 48 h. Twenty-seven hours
after thawing cells were activated with Dynabeads Human T-
Activator CD3/CD28 (Gibco, Cat. N. 11131D) according to
the manufacturer’s instructions. Cells were transduced after an
additional 24 h with anMOI of 10 and then expanded for 11 days
at a concentration of 0.5× 106 to 1.5× 106 T-cells/ml.
T-Cell Expansion After Repeated
Challenges With Target Cells
To analyze T-cell proliferation capacity after antigen encounter,
we seeded a co-culture of CAR-T cells and NALM6 cells at 1:1
ratio (250,000 cells each). After 4 days of incubation, an aliquot of
the culture was taken and analyzed to determine T-cell number.
Cells were labeled with CD3, CD4, CD8, and CD19, and then 20
µl of beads (CountBright, Cat. N. C36950, Invitrogen) was added
to the sample to determine absolute cell number. This process
was repeated 3 times.
Statistics
Statistical significance was assessed using SPSS software.
Unpaired T-test was used unless otherwise specified. U-Mann
Whitney was used for comparison of variables with non-normal




Twenty-eight apheresis products were obtained from 27 patients
included in the clinical trial. For one patient, the apheresis
product was obtained twice due to ARI-0001 cell production
failure (T10 and T13 products belong to the same patient).
Description of apheresis products is presented in Table 2.
Patients’ apheresis products were subjected to CD4+ and CD8+
magnetic selection using the CliniMACS Prodigy system. In all
cases except for one (Patient T27), the minimum number of T-
cells (100 × 106) was obtained (Table 2). In Patient T27, cell
culture was initiated with 50× 106 cells.
Results of cell expansion in CliniMACS Prodigy for the 27
products are presented in Figures 1A,B and Table S2. Cells were
expanded for an average of 8.5 days, range 7–10. Average total
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TABLE 2 | Apheresis products composition and CD4-CD8 cell selection.
Pat. ID Disease Apheresis products CD4-CD8 selection
WBC (×109) Lymph (×109) CD3+ (%)* CD4+ (%)* CD8+ (%)* Total cell number (×106)
T01 Adult ALL 7.15 6.40 24.80 12.60 10.70 960
T02 NHL 3.31 1.56 32.50 11.40 19.80 1,200
T03 Pediatric ALL 4.59 3.50 49.38 22.67 26.71 1,580
T04 NHL 4.04 0.85 13.50 6.60 6.20 488
T05 NHL 7.71 4.23 30.00 12.10 15.50 1,800
T06 Adult ALL 3.64 3.19 28.80 10.60 16.20 720
T07 Adult ALL 4.91 3.84 29.00 4.40 19.80 1,900
T08 CLL 2.88 2.30 19.70 8.80 10.10 1,560
T09 Pediatric ALL 4.27 3.24 21.50 11.30 8.80 1,442
T10 Adult ALL 1.00 0.72 15.30 7.90 6.10 350
T11 Adult ALL 2.08 0.98 13.90 7.90 4.40 360
T12 Pediatric ALL 8.40 6.21 2.20 1.70 0.50 150
T13 Adult ALL 1.29 0.64 26.90 8.40 15.60 250
T14 Adult ALL 3.22 2.31 38.90 17.80 18.00 2,160
T15 Adult ALL 2.88 1.28 26.10 8.70 14.50 1,050
T16 Pediatric ALL 1.98 1.22 22.60 4.80 15.90 400
T17 Adult ALL 8.55 2.82 27.90 7.40 19.20 1,400
T19 Pediatric ALL 1.09 0.20 22.50 12.80 7.50 250
T20 Adult ALL 3.73 2.23 28.60 7.20 20.70 760
T21 Pediatric ALL 4.50 2.20 36.20 18.60 14.20 400
T22 Adult ALL 8.37 3.16 42.00 21.40 19.50 750
T24 Adult ALL 25.85 22.00 4.10 1.20 0.70 200
T25 Adult ALL 0.83 0.46 32.50 5.50 25.70 1,520
T26 Pediatric ALL 0.84 0.51 6.50 1.40 4.60 200
T27 Adult ALL 0.33 0.10 10.00 3.30 6.10 50
T30 Adult ALL 2.06 1.48 46.50 13.20 28.80 871
T32 Adult ALL 2.23 0.69 52.00 19.30 27.40 2,000
T34 NHL 6.71 3.54 23.50 12.60 9.70 993
*% of cells over WBC.
cell number obtained in the final product was 2,548 × 106,
range 600 × 106 to 5,200 × 106. In one patient where cell
culture was started with 50 × 106 cells, the final product also
met acceptance criteria. In this particular case, cell culture was
maintained for 13 days, finally obtaining 3,300 × 106 cells.
When compared to healthy donors (used in three previous
validation runs), patient cells seem to expand more slowly,
even if the number of runs performed with healthy donors is
limited (Figure 1C).
Products were analyzed in terms of appearance, quantity,
identity, purity, safety, and potency. A complete list of product
specifications is provided in Table S1.
Product Purity and Transduction Efficiency
The final product was characterized in terms of cell viability,
percentage of CD3+ cells and percentage of CAR+ cells. This
data is summarized in Table 3. All products met acceptance
criteria for cell viability and percentage of CD3+ cells (>70% for
both parameters). The lowest value detected for cell viability was
91 and 85.7% for CD3+ cells (Figure 1D).
To analyze the percentage of CAR+ cells, we first validated our
detection method based on the use of an APC-conjugated F(ab’)2
anti-mouse antibody. To this end, we engineered a vector where
CAR19 and GFP were co-expressed. As shown in Figure S2,
the correlation between GFP+APC+ or GFP–APC– cells was of
93.5%, thereby indicating that the detection method had a good
sensitivity and specificity.
Using this detection system, we assessed the percentage of
CAR+ (ARI-0001) cells in the patients’ products. All products
except one met the specification of >20% ARI-0001 cells. In
one product (T10) only 14.5% ARI-0001 cells were detected.
Consequently, this product was considered a production failure.
CAR T-cell production was repeated for this patient from
a 2nd apheresis (T13). This time, a valid product could be
obtained. Mean (±SD) of percentage of CAR+ cells in this
series was 30.6 ± 13.44 (Figures 1B–D), slightly lower than
transduction efficiencies achieved in small-scale expansions
(45.3%) (Figure S1A). No significant differences in efficiency
of transduction were observed between healthy donors and
patients (35.8 vs. 30.6%), or among the different diseases
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FIGURE 1 | ARI-0001-cell expansion in CliniMACS Prodigy. (A) Expansion kinetics of ARI-0001-cell products (Total cell number). Gray points indicate individual
products. Black triangles indicate Mean ± SD and adjusting curve. (B) Expansion kinetics of CAR19+ cells (red) and total cell number (black). Mean ± SD is
represented. (C) Expansion kinetics of ARI-0001 cells (Total cell number) comparing healthy controls and different types of disease. Mean ± SEM is represented. (D)
Percentage of CD3 and CAR19 positive cells as determined by flow cytometry. Mean ± SD is also indicated. Panels on the right show flow cytometry representative
image corresponding to CAR19 and CD3 staining in ARI-0001-cell final products and Control T cells (Untransduced).
(Figure S1B). Percentage of CAR+ cells over time during cell
expansion was also investigated. A high degree of variability
was detected among patients, with the percentage of CAR+
cells increasing in some patients while decreasing in others
(Figure S3). In terms of number of cell doses obtained per
patient, considering a standard weight of 70 kg for adults and
25 kg for pediatric patients, a minimum of two cell doses were
quickly obtained (by day 7) for all ALL patients (dose 1 × 106
ARI-0001 cells/kg). For NHL patients (dose 5 × 106 ARI-0001
cells/kg), two cell doses were obtained for three out of four
patients, by day 9. Indeed, the number of cell doses obtained
for ALL far exceeded the need (nine cell doses for adult patients
and 25.4 for pediatric patients), indicating that the time of
ex vivo cell expansion could be reduced if necessary in these
groups of patients. For NHL, the average number of ARI-
0001 cell doses obtained was 2.5. Only one CLL patient has
been produced so far. T-cells from this patient grew slower
and required 10 days of expansion, finally obtaining 398 × 106
ARI-0001 cells.
CAR19 transduction was also assessed in terms of DNA
copies/cell. As shown in Table 3 CAR19 was detected in all
products, within a range of 0.4–2.9 copies/cell (all below
the limit considered safe of <10 copies/cell). As expected,
a positive correlation between percentage of CAR+ cells
and DNA copies/cell was obtained, further validating both
techniques (Figure S4).
Product Potency
Cytotoxic potential was analyzed in vitro for each product before
infusion. A co-culture of the final product with NALM6 cell line
was initiated at different E:T ratios. Percentage of alive-CD19+
cells was measured by flow cytometry after 4 h. As a control, the
cytotoxic activity of non-transduced CD4+CD8+ cells from the
same patient was also measured. Products were considered valid
when the CD19+ cell surviving fraction with ARI-0001 cells, at
ratio 1:1, was lower than 70%. Results are presented in Table 3
and Figure 2A. All products obtained met the specification of
<70% CD19+ surviving fraction at E:T ratio 1:1, indicating that
all products prepared had the intrinsic capacity of eliminating
CD19+ cells.
Cytokine level was also measured in the supernatant of
cytotoxicity assays. As expected, increased levels of pro-
inflammatory cytokines such as IFNγ and TNFα was observed
when ARI-0001 cells were co-cultured with NALM6, compared
to ARI-0001 cells alone. The level of GranzymeB was also
significantly increased (Figure 2B) consistent with the cytotoxic
activity of ARI-0001 cells. The complete set of analyzed cytokines
is provided in Figure S5.
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TABLE 3 | ARI-0001 product characterization.
Pat. ID Cell viability %CD3+ %CAR+ Sterility Mycoplasma Endotoxin Adventitious virus Transgene copies/cell RCL Potency
T01 100 94.7 39.3 Sterile Absent <0.5 EU/ml Absent 1.05 Absent 13.9
T02 95 96.5 28 Sterile Absent <0.5 EU/ml Absent 0.92 Absent 6.0
T03 90 96.0 30 Sterile Absent <0.5 EU/ml Absent 0.97 Absent 2.7
T04 98 98.1 22.8 Sterile Absent <0.5 EU/ml Absent 0.66 Absent 17.2
T05 93 98.4 22.9 Sterile Absent <0.5 EU/ml Absent 0.9 Absent 41.4
T06 96 87.1 43.6 Sterile Absent <0.5 EU/ml Absent 1.55 Absent 0.6
T07 96 97.3 20.4 Sterile Absent <0.5 EU/ml Absent 0.73 Absent 18.6
T08 92 98.7 20.7 Sterile Absent <0.5 EU/ml Absent 1.62 Absent 21.4
T09 100 99.1 20.6 Sterile Absent <0.5 EU/ml Absent 0.77 Absent 8.7
T10 98 98.7 14.5* – – – – – – –
T11 94 99.7 25 Sterile Absent <0.5 EU/ml Absent 2.31 Absent 0.04
T12 98 99.4 20 Sterile Absent <0.5 EU/ml Absent 0.43 Absent 14.4
T13 95 99.2 20.4 Sterile Absent <0.5 EU/ml Absent 0.57 Absent 3.5
T14 98 99.2 62.2 Sterile Absent <0.5 EU/ml Absent 1.99 Absent 0.01
T15 93 97.5 34.4 Sterile Absent <0.5 EU/ml Absent 1.98 Absent 1.4
T16 91 98.7 26.6 Sterile Absent <0.5 EU/ml Absent 1.46 Absent 0.1
T17 96 94.8 26 Sterile Absent <0.5 EU/ml Absent 1.47 Absent 0.2
T19 93 90.6 22.6 Sterile Absent <0.5 EU/ml Absent 0.99 Absent 0.3
T20 94 98.3 20.8 Sterile Absent <0.5 EU/ml Absent 1.15 Absent 0.02
T21 91 99.4 48.2 Sterile Absent <0.5 EU/ml Absent 1.59 Absent 0.0
T22 82 97.3 44.1 Sterile Absent <0.5 EU/ml Absent 2.1 Absent 0.0
T24 97 99.7 23.8 Sterile Absent <0.5 EU/ml Absent 1.55 Absent 4.18
T25 94 98.2 41.5 Sterile Absent <0.5 EU/ml Absent 2.92 Absent 0.06
T26 97 98.5 23 Sterile Absent <0.5 EU/ml Absent 0.4 Absent 28.0
T27 98 96.5 23.2 Sterile Absent <0.5 EU/ml Absent 0.62 Absent 4.3
T30 95 85.7 26 Sterile Absent <0.5 EU/ml Absent 2.08 Absent 0.2
T32 97 98.2 35.6 Sterile Absent <0.5 EU/ml Absent 1.93 Absent 0.2
T34 94 99.1 71.5 Sterile Absent <0.5 EU/ml Absent 2.93 Absent 0.02
*Value below acceptance criteria.
CAR T-cells produced from patients were compared to
those obtained from healthy controls in terms of cytotoxic
activity and cytokine production. As shown in Figure 2C,
patients’ and healthy donors’ CAR T-cells showed similar
cytotoxic potential (even slightly higher for patient’s cells
although this was not statistically significant). Production of pro-
inflammatory cytokines (IFNγ and TNFα) and GranzymeB was
also comparable (Figure 2D).
T Cell Subset Characterization
Product composition was further analyzed in terms of CD4/CD8
ratio and TN, TSCM, TCM, TE, and TEM subsets. Consistent with
previous reports (38), CD4/CD8 ratio was inverted (CD4/CD8
ratio < 1) in a large subset of patients that were candidate
for a CAR T-cell therapy (Figure 3A). Average CD4/CD8 ratio
was 0.93 ± 0.67 in the apheresis products. This ratio was not
significantly altered after CD4 and CD8 cell selection in the
vast majority of patients. However, a significant increase in the
proportion of CD4 cells was detected during cell expansion.
CD4/CD8 ratio increased from 0.64 ± 0.61 after CD4-CD8 cell
selection, to 1.61 ± 1.04 in the final product. A deeper analysis
of this data reveled that in patients starting with a CD4/CD8
ratio < 1, the proportion of CD4+ cells tended to increase
during cell expansion, while in patients where a CD4/CD8
ratio > 1 was obtained after cell selection, the proportion
of CD4+ cells tended to decrease (Figure 3B). Therefore, the
difference in CD4/CD8 ratio (1CD4/CD8) before and after
cell expansion was significantly different depending on the
initial ratio (Figure S6A). The efficiency of transduction differed
between CD4+ and CD8+ subsets, as CD4 showed a significantly
higher percentage of CAR+ cells (Figure 3C).
In terms of TN, TSCM, TCM, TE, and TEM subsets, we observed
a high degree of variability among patients’ final products
(Figure 3D). This high variability is exemplified by the different
level of CD45RA and CCR7 expression in samples from different
patients (Figures 3E,F) and cannot be attributed to the different
diseases (Figure S1C). Within the CAR+ T-cells of the final
product, memory phenotypes (CM and EM) predominated in
the vast majority of patients. Average percentage and SD for each
subpopulation in the CAR+ cells of the final product is as follows:
TN: 7.71 ± 13.9, TSCM: 5.26 ± 12.0, TCM: 31.01 ± 16.7, TEM:
35.11 ± 17.7, and TE: 4.2 ± 9.5. Analysis of CD4 and CD8 cells
separately showed that CD8 cells have amore TN, TSCM, and TCM
phenotype than CD4 cells (Figure S6B). We also analyzed how
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FIGURE 2 | ARI-0001-cell potency. (A) Cytotoxicity assay after 4 h of ARI-0001 co-culture with NALM6 cells, at the indicated ratios. Mean ± SD of all 27 CAR T cell
products is indicated. (#) Dashed line indicates minimum of ARI-0001-cell cytotoxicity level for a product to be considered valid. (B) IFNγ, TNFα, and GranzymeB
levels measured in the supernatants of the cytotoxicity assays. E:T ratio 0 indicates no target cells. (*) indicates statistical significance, p < 0.05. (C) Comparison of
ARI-0001 cytotoxic potential after 4 h of co-culture with NALM6 cells, at the indicated ratios. Mean ± SD is shown. “n.s.” indicates not statistically significant (Non
parametric test). (D) Comparison of IFNγ, TNFα, and GranzymeB levels measured in the supernatants of the cytotoxicity assay at E:T ratio 1:1. “HD” indicates Healthy
donors. “n.s.” indicates not statistically significant (Parametric test applied to IFNγ and TNFα and non-parametric test applied to GranzymeB).
these subsets varied during ex vivo cell expansion by comparing
T-cell subsets in the initial (after CD4-CD8 cell selection) and
in the final product, and if CAR expression influenced T-cell
subpopulations (CAR– vs. CAR+ cells). As shown in Figure 3D,
we observed a robust increase in the proportion of TCM during
cell expansion while TN and TEFF cells decreased. These changes
in T-cell subsets can be attributed to a decrease in CD45RA
expression which is expected upon cell activation (Figures 3E,F).
No statistically significant changes in the T-cell subsets were
detected between CAR– and CAR+ cells in the final product,
although a further increase in TCM, and consequent decrease
in TEFF cells, was observed in CAR+ cells compared to CAR–
(Figure 3D). Consistently, a small increase in CCR7 expression
was also detected in CAR+ cells vs. CAR- cells. (Figure 3F).
The impact of CAR expression on CCR7 was further explored
in independent small-scale expansions (see next section). The
changes in expression of CD27, CD28, and CD95 were also
assessed by flow cytometry. As shown in Figure S6C, CD95
was increased during cell expansion and CD27 decreased. CD28
did not show significant changes during expansion, although
presented a higher expression in CAR+ compared to CAR- cells.
Small-Scale CAR T Cell Expansions
To further evaluate the impact of culture conditions or CAR
expression on the proportion of CD4/CD8 ratio or T-cell
phenotype, cell expansions from patients’ selected cells were
repeated in a small scale experiment, under different conditions.
We selected six of the patients (three adult ALL and three NHL)
from which frozen leftover cells after CD4-CD8 cell selection
were available. We expanded patients’ cells in four different
conditions: (1a) IL2—Untransduced T-cells, (1b) IL2—CAR T-
cells, (2a) IL7/IL15—Untransduced T-cells, (2b) IL7/IL15—CAR
T-cells. As shown in Figure S7A, cells expanded between 17
and 100 times over a period of 11 days. CAR19 transduced
T-cells expanded less (or slowly) compared to untransduced
counterparts, and IL2 grown cells expanded more than IL7/IL15
(in both untransduced and CAR19 conditions) (Figure S7B).
Cell transduction or cytokines used did not condition CD4/CD8
ratio in a consistent way. However, as detected previously in
the products expanded using the Prodigy system, in patients
starting with CD4/CD8 ratio>1 (T04 and T34), the ratio tended
to decrease, while in patients starting with CD4/CD8 ratio
< 1 (T02, T15, T22, and T34), the ratio tended to increase
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FIGURE 3 | ARI-0001 cell subset characterization. (A) CD4/CD8 ratio of apheresis products, after CD4-CD8 cell selection and of the final product. (B) CD4/CD8 ratio
variation during cell expansion. Left panel corresponds to products with an initial ratio < 1. Right panel corresponds to products with an initial ratio > 1. (C) CAR19
transduction efficiency in CD4 and CD8 cells. Mean ± SD is shown. (D) Percentage of T-cell subpopulations within initial (CD4-CD8 cell selection) and final products
(CAR– and CAR+ cells). (E) Representative flow cytometry plots of three different patients showing T cell populations in initial and final products. (F) Differences in MFI
for CD45RA and CCR7 in initial and final products. Lower panel shows paired analysis for CCR7 MFI. (*) indicates statistical significance, p < 0.05. n.s. indicates not
statistically significant.
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(Figure S7C). Indeed, since the expansions were maintained for
longer in the small-scale expansions than in the Prodigy system,
we observed that the ratio CD4/CD8 may fluctuate in a more or
less pronounced way, but it tends to CD4/CD8= 1 if the cells are
cultured for longer periods of time.
Interestingly, significant differences were found in terms of T-
cell subsets depending on the culture conditions. The cytokines
used in the growth media did not provide significant differences
in terms of the different subsets in this series of patients.
However, a significant and consistent difference was appreciated
in CAR19 expressing cells vs. untransduced T-cells for almost
all subsets. As shown in Figure S7D, CAR19 transduction
resulted in a much higher percentage of TN, TSCM and TCM
subsets independently of the cytokine used in the culture media.
By contrary, TEM cells were decreased in the CAR19+ cells
compared to the untransduced samples. In this case, no difference
in CD45RA MFI between untransduced and CAR19+ cells was
observed that can account for the decrease in TN and TSCM, since
in both conditions, cells were activated and proliferated ex vivo.
However, we observed a significant increase in CCR7 expression
in CAR19+ cells compared to untransduced cells (Figure S7E).
This increase explains a higher percentage of TN, TSCM, and
TCM subsets and lower TEM. Increase in CCR7 expression upon
4-1BB activation has been previously described in monocytes
(39) and also proposed for CAR T-cells (40). To test if 4-1BB
activation is responsible for the increase in CCR7 we observe in
the CAR+ cells, we modified our CAR construct by changing
the co-stimulatory domain to CD28 (Figure S8A). T-cells from
a healthy donor were then left untransduced or transduced
with the 4-1BB- or CD28-containing CARs and expanded in
vitro for 10 days. Again, we observed an increase in CCR7
expression in the CAR-positive fraction of the cells transduced
with the 4-1BB-containing construct, compared to untransduced
cells or CD28-containing CAR+ cells (Figure S8B). As expected,
percentage of TCM cells is also higher in 4-1BB-containing CAR+
cells (Figure S8C).
Finally, the functionality of CAR T-cells manufactured
with the Prodigy system and small-scale expansions was
also compared. For this comparison, cells from 3 patients
expanded with IL-7/IL-15 were used. The production of pro-
inflammatory cytokines, cytotoxic potential and T-cell expansion
was measured after adjusting for the same percentage of CAR+
cells. Production of IFNγ and TNFα was measured after co-
culture of CAR T-cells with NALM6 at 1:1 ratio, at 4 h
time-point. Level of these two cytokines was measured both
by intracellular staining (Figure S9A) and cytokines present
in the media (Figure S9B), yielding consistent results. Cells
manufactured in the Prodigy system consistently produced
slightly more IFNγ and TNFα than cells manufactured in small-
scale expansions. However, these differences were not statistically
significant. In terms of cytotoxic potential, cells produced with
both methods showed comparable results (Figure S9C). Finally,
T-cell expansion upon repeated challenges with fresh target cells
(NALM6) was slightly higher in cells manufactured with the
Prodigy system than with small-scale expansions, although it
did not reach statistical significance (Figure S9D). Therefore, we
conclude that cells manufactured with the Prodigy system are
functionally comparable, or even slightly more active, than those
produced in small-scale expansions.
Taking all this data together, we conclude that ex vivo cell
expansion causes a loss of TN and TEFF, which is observed in both
the Prodigy system and small-scale expansions. On the contrary,
TCM cells are largely accumulated, both by ex vivo expansion and
as a result of CAR expression (in CARs containing 4-1BB as a
co-stimulatory domain). Cells produced in Prodigy system are
functionally similar to those produced in small-scale expansions.
DISCUSSION
CAR T-cells are complex medical products. Most of the
approaches explored so far are based on the use of autologous
CAR T-cells, thereby requiring the production of a personalized
product for each patient.Moreover, CART-cells are gene-therapy
products, involving clinical-grade preparation of vectors, and
subsequent T-cell selection, transduction and expansion. Two
different CAR T-products (Yescarta, Kite-Gilead and Kymriah,
Novartis) have already been approved for the treatment of
pediatric-ALL and NHL. Nonetheless, the development of new
CAR T-products, including phase I and II clinical trials, for
many different targets and diseases is primarily conducted in
academic research centers. Manufacturing of clinical-grade CAR
T-cells can pose a challenge for many medium-sized academic
institutions. We have previously published the development of
our own CAR19 product (based on the scFv sequence of A3B1
antibody) and the establishment of a CAR T-cell production
protocol and infrastructure, based on the use of CliniMACS
Prodigy, a semi-automated closed system by Miltenyi (37).
We and others have previously demonstrated the feasibility
of CAR T-cell manufacturing from healthy donors, using
CliniMACS Prodigy (41–45). Now, we report the preparation
and characterization of 27 CAR T-cell products for ALL, CLL,
or NHL patients.
Patients eligible for CAR T-cell therapies have previously
received multiple lines of therapies. As a result, T-cells from
these patients have a reduced proliferation capacity and
abnormal CD4/CD8 ratio compared to healthy donors (46,
47). Nevertheless, we have been able to obtain 27 valid CAR
T-cell products (according to the specifications indicated in
Table S1) out of 28 attempts, proving the feasibility of CAR T-cell
manufacturing for heavily pre-treated patients using the Prodigy
system. Cell expansion was maintained for an average of 8.5 days.
Indeed, patient-derived T-cells expand more slowly compared to
the expansions performed from healthy T-cell donors. However,
for ALL patients, where the infused dose is typically 1 × 106
CAR T-cells/kg, a minimum of 2 CAR T-cell doses were already
achieved by day 7 in a 100% of patients, indicating that it is
possible to reduce the expansion time in this subset of patients
(actual expansion time was 8.4 days, due to pre-scheduled
work plans). CLL and NHL patients required 9–10 days of
expansion due to reduced intrinsic T-cell proliferation (48, 49)
and higher CAR T-cell numbers needed, respectively. Reduced
T-cell expansion time is highly desirable, not only to reduce
the cost of batch production and to shorten the time until the
patient can receive the treatment, but also for the quality of the
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product obtained, as discussed below. Despite reduced expansion
capacity of heavily pretreated patient’s T-cells compared to
healthy donors, we have observed equivalent product potency
in terms of cytotoxic potential and pro-inflammatory cytokine
production. The method of CAR T-cell production (Prodigy
vs. small-scale) yielded also comparable products in terms of
product potency, or even slightly more active in cells obtained
with Prodigy. We reasoned that the higher cell densities reached
in the Prodigy system may be advantageous for T-cell fitness
and potency.
Average transduction efficiency was 30.6% on average in
our series and does not differ significantly between patients
and healthy controls. Similar transduction efficiencies have
been reported by other groups using CliniMACS Prodigy for
production of CAR T-cells from healthy controls (41, 50–52),
except one study that reports transduction efficiencies between
50–60% using very high MOI (MOI = 100) (44). Transduction
efficiency in small-scale CAR-T cell productions is slightly higher
(45.3 vs. 30.6%). We can speculate that having the possibility
to put in direct contact cells and lentivirus, i.e., spinoculation,
or adding reagents to the media that facilitate the entry of the
lentivirus to the cells (such as polybrene) could help increase
transduction efficiency in the Prodigy system.
We observed a preference of CD4+ cell expansion over
CD8+ ex vivo. This is consistent with previous observations
from other groups using different expansion systems and CAR
constructs (53, 54). Gomes-Silva and co-workers reported a
preferential expansion of CD4 cells when using a 4-1BB co-
stimulatory domain compared to a CD28-containing CAR (55).
Therefore, this effect may contribute partially to explain this
phenomenon. Indeed, we detected a higher fraction of CD4-
transduced cells than CD8. Nevertheless, we have clearly shown
than CD4/CD8 ratios are highly dependent on the initial ratio
and tend to equilibrium in longer ex vivo expansions, indicating
that preferential CD4 expansion may be transitory and fluctuate
also after CAR T-cell infusion.
TN, TSCM, and TCM phenotypes have been associated to
longer persistence in vivo and higher anti-tumor efficacy (38,
56–58). We have dissected the factors that determine these T-
cell populations with the aim of analyzing if our production
system could be optimized. Indeed, there is a very high degree
of variability in T-cell phenotypes among patients, which highly
determines final product composition. In our experimental
setting, both IL-7/IL-15 and IL-2 yielded comparable population
phenotypes. In most patients, ex vivo cell culture led to a decrease
in the fraction of CD45RA positive cells in the final product.
Loss of CD45RA expression is expected upon cell activation and
proliferation, and therefore intrinsic to ex vivo cell expansion,
resulting in decreased numbers of TN cells (38, 40, 59, 60). In
this regard, shortening the time of ex vivo cell expansion when
possible may help preserve this population. TCM cells have also
been shown to be able to establish persistent T-cell memory
(58) and have superior anti-tumor effects (38). Therefore, the
loss of TN cells may not have a major impact in anti-tumor
efficacy, since most of them are converted to TCM cells. Actually,
memory phenotypes are the most represented populations in
our CAR T final products, consistent with previous reports (53).
4-1BB-containing CAR T-cells have been shown to have an
increased proportion of TCM compared to CD28-containg CARs,
which have a predominant TEM population (40, 55). We have
shown that the increase in TCM cells is not only the result of
CD45RA loss, but also due to increased CCR7 expression in 4-
1BB-containing CAR-expressing cells [our data and Kawalekar
et al. (40)]. This data correlates with a longer CAR T-cell
persistence in vivo of 4-1BB- compared to CD28-containing
CARs (11, 12, 49).
In conclusion, we have demonstrated for the first time
the feasibility of CAR T-cell manufacturing for heavily pre-
treated ALL, CLL, and NHL patients, using CliniMACS Prodigy.
To our knowledge, this is the first report describing the
characteristics of the products obtained with this system,
including a medium-large cohort of patients. Our study shows
that CAR T-cell manufacturing can be completed in as
low as 7 days for ALL patients and that reduced ex vivo
expansion time may yield CAR T-cell products with increased
persistence in vivo. The products obtained show potent anti-
tumor efficacy and are characterized by a predominance of TCM
and TEM phenotypes.
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